148 related articles for article (PubMed ID: 16422998)
1. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease.
Dilger K; Alberer M; Busch A; Enninger A; Behrens R; Koletzko S; Stern M; Beckmann C; Gleiter CH
Aliment Pharmacol Ther; 2006 Feb; 23(3):387-96. PubMed ID: 16422998
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamic action of budesonide after buccal administration in healthy subjects and patients with oral chronic graft-versus-host disease.
Dilger K; Halter J; Bertz H; Lopez-Lazaro L; Gratwohl A; Finke J
Biol Blood Marrow Transplant; 2009 Mar; 15(3):336-43. PubMed ID: 19203724
[TBL] [Abstract][Full Text] [Related]
3. Budesonide for Crohn's disease.
Seow CH; Benchimol EI; Steinhart AH; Griffiths AM; Otley AR
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):971-9. PubMed ID: 19611401
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis.
Hempfling W; Grunhage F; Dilger K; Reichel C; Beuers U; Sauerbruch T
Hepatology; 2003 Jul; 38(1):196-202. PubMed ID: 12830002
[TBL] [Abstract][Full Text] [Related]
5. Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: a double drug interaction study.
Dilger K; Fux R; Röck D; Mörike K; Gleiter CH
J Clin Pharmacol; 2007 Dec; 47(12):1532-9. PubMed ID: 18048573
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease.
Lundin PD; Edsbäcker S; Bergstrand M; Ejderhamn J; Linander H; Högberg L; Persson T; Escher JC; Lindquist B
Aliment Pharmacol Ther; 2003 Jan; 17(1):85-92. PubMed ID: 12492736
[TBL] [Abstract][Full Text] [Related]
7. Oral budesonide in the management of Crohn's disease.
Hofer KN
Ann Pharmacother; 2003 Oct; 37(10):1457-64. PubMed ID: 14519035
[TBL] [Abstract][Full Text] [Related]
8. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Feagan BG; Sandborn WJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
[TBL] [Abstract][Full Text] [Related]
9. Budesonide in glucocorticoid dependent chronic active Crohn's disease; a pilot study.
Novacek G; Kleinberger M; Vogelsang H; Moser G; Lochs H
Z Gastroenterol; 1995 May; 33(5):251-4. PubMed ID: 7610692
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids.
Meibohm B; Derendorf H; Möllmann H; Fröhlich P; Tromm A; Wagner M; Homrighausen S; Krieg M; Hochhaus G
Int J Clin Pharmacol Ther; 1999 Aug; 37(8):367-76. PubMed ID: 10475139
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease.
Edsbäcker S; Andersson T
Clin Pharmacokinet; 2004; 43(12):803-21. PubMed ID: 15355126
[TBL] [Abstract][Full Text] [Related]
12. Beclomethasone dipropionate for the treatment of mild-to-moderate Crohn's disease: an open-label, budesonide-controlled, randomized study.
Tursi A; Giorgetti GM; Brandimarte G; Elisei W; Aiello F
Med Sci Monit; 2006 Jun; 12(6):PI29-32. PubMed ID: 16733496
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of high intestinal output syndrome with budesonide in patients with Crohn's disease and ileostomy.
Ecker KW; Stallmach A; Löffler J; Greinwald R; Achenbach U
Dis Colon Rectum; 2005 Feb; 48(2):237-42. PubMed ID: 15714248
[TBL] [Abstract][Full Text] [Related]
14. Budesonide: its role in Crohn's disease therapy.
Coleman CI; Reddy P; White CM
Conn Med; 2002 Sep; 66(9):523-6. PubMed ID: 12369546
[No Abstract] [Full Text] [Related]
15. Effect of steroids on energy expenditure and substrate oxidation in women with Crohn's disease.
Al-Jaouni R; Schneider SM; Piche T; Rampal P; Hébuterne X
Am J Gastroenterol; 2002 Nov; 97(11):2843-9. PubMed ID: 12425558
[TBL] [Abstract][Full Text] [Related]
16. Treatment of active Crohn's ileocolitis with oral pH-modified budesonide. Germany Budesonide Study Group.
Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
Z Gastroenterol; 1995 May; 33(5):247-50. PubMed ID: 7610691
[TBL] [Abstract][Full Text] [Related]
17. Budesonide modified-release capsules.
Baker DE
Rev Gastroenterol Disord; 2001; 1(3):147-55. PubMed ID: 12120182
[TBL] [Abstract][Full Text] [Related]
18. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission.
de Jong DJ; Bac DJ; Tan G; de Boer SY; Grabowsky IL; Jansen JB; Greinwald R; Naber TH
Neth J Med; 2007 Oct; 65(9):339-45. PubMed ID: 17954953
[TBL] [Abstract][Full Text] [Related]
19. The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide.
Hermann R; Siegmund W; Giessmann T; Westphal K; Weinbrenner A; Hauns B; Reutter F; Lahu G; Zech K; Bethke TD
J Clin Pharmacol; 2007 Aug; 47(8):1005-13. PubMed ID: 17660483
[TBL] [Abstract][Full Text] [Related]
20. No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis.
Dilger K; Denk A; Heeg MH; Beuers U
Hepatology; 2005 Mar; 41(3):595-602. PubMed ID: 15726657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
